Loading...
•
Sep 30, 2023
MannKind Q3 2023 Earnings Report
MannKind reported a strong quarter with significant revenue growth, driven by Tyvaso DPI royalties and Afrezza sales.
Key Takeaways
MannKind Corporation reported a strong third quarter in 2023, with total revenues of $51 million, a 56% increase compared to Q3 2022. Net income was $2 million, and non-GAAP net income reached $4 million. The company's growth was primarily driven by Tyvaso DPI royalties and increased Afrezza sales.
Total revenues reached $51 million, representing a 56% increase compared to Q3 2022.
Net income was reported at $2 million, with a non-GAAP net income of $4 million.
Tyvaso DPI royalties significantly increased by 225% compared to Q3 2022, reaching $20 million.
Endocrine BU net revenues were $18 million, with Afrezza net revenues increasing by 24% compared to Q3 2022.
Revenue by Segment
Forward Guidance
MannKind expects to continue executing its commercial operating plan and funding its pipeline development efforts, driven by the continued success of Tyvaso DPI.
Positive Outlook
- Continued success of Tyvaso DPI.
- Ability to execute commercial operating plan.
- Funding of pipeline development efforts.
- Strong revenue growth.
- Potential for future growth and expansion.
Challenges Ahead
- Risks associated with manufacturing and supply.
- Risks associated with product commercialization.
- Risks associated with developing product candidates.
- Risks associated with MannKind’s ability to manage its existing cash resources or raise additional cash resources.
- Other risks detailed in MannKind’s filings with the SEC.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...